Pfizer quits Duchenne gene therapy, lays off staff following study setback
Bio Pharma Dive
JULY 30, 2024
The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.
Sat.Jul 27, 2024 - Fri.Aug 02, 2024
340 
One Diet Choice While Pregnant May Protect Your Child’s Heart For Life
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 31, 2024
The food consumed by a pregnant mother just got a little bit more important. According to a new study on pregnant mice, a diet rich in fiber improves the long-term heart health of developing offspring, significantly lowering their risk of cardiovascular disease later in life.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Understanding ICH Guideline Q14
Pharmaceutical Technology
AUGUST 1, 2024
Q14 is a new guideline detailing the elements of minimal and enhanced approaches for analytical procedure development. While the traditional minimal development approach remains valid, the advanced approach employing QbD principles requires additional development data and knowledge.
Another IRA lawsuit bites the dust with ruling on Novo Nordisk case; company pledges to appeal
Fierce Pharma
AUGUST 1, 2024
Like clockwork, another lawsuit challenging the constitutionality of the Inflation Reduction Act's (IRA's) price-setting measures has been shot down in the courts. | The ruling from the New Jersey federal court marks the latest in a string of rejections as various drugmakers have taken to the courts to fight the drug pricing legislation.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bateman Horne Center leads the way in ME/CFS and long COVID education
BioPharma Reporter
AUGUST 1, 2024
The Bateman Horne Center of Excellence (BHC) has established itself as a trusted leader in the clinical care, provider education, patient advocacy, and research of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID.
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
Bio Pharma Dive
AUGUST 2, 2024
Adaptimmune’s Tecelra is the first TCR cell therapy to reach market and, at $727,000, is also the priciest cellular medicine for cancer in the U.S.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Here’s What ‘Diet’ Soft Drink Could Be Doing to Your Health in The Long Term
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 1, 2024
Many people are drinking less sugary soft drink than in the past. This is a great win for public health, given the recognised risks of diets high in sugar-sweetened drinks. But over time, intake of diet soft drinks has grown. In fact, it’s so high that these products are now regularly detected in wastewater.
Study finds 3D-printed blood vessels could improve heart bypass outcomes
Pharma Times
JULY 29, 2024
Coronary heart disease is the most common form of heart and circulatory disease
Lilly obesity drug shows heart benefit in late-stage trial
Bio Pharma Dive
AUGUST 1, 2024
The drug led to a 38% reduction in the risk of death or complications from a type of heart failure, a finding that compared favorably to available treatments.
AbbVie acquires Cerevel Therapeutics for $8.7bn
Pharmaceutical Technology
AUGUST 2, 2024
AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Ancient Genes of Zombie Viruses Revealed as Hidden Drivers of Cancer
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 30, 2024
When viruses pay us a visit, they sometimes leave parts of themselves behind. Silently tucked away in our genomes, some of these bits of foreign DNA can get passed down through the generations.
EPSRC launches two new hubs to transform early disease diagnosis in the UK
Pharma Times
JULY 31, 2024
Quantum-based technologies will explore infectious diseases, cancer and dementia
Moderna shares fall amid lower sales outlook for RSV, COVID shots
Bio Pharma Dive
AUGUST 1, 2024
The biotech cited competitive pressure and “very low” expected sales in Europe for its latest guidance cut, which sent shares down by nearly 20%.
Otsuka snaps up Jnana with its phenylketonuria drug for $800m
Pharmaceutical Technology
AUGUST 1, 2024
The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s phenylketonuria therapy to its portfolio.
Blue Light From Your Phone Really Can Affect Your Skin. Here’s How.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 29, 2024
Social media is full of claims that everyday habits can harm your skin. It’s also full of recommendations or advertisements for products that can protect you. Now social media has blue light from our devices in its sights. So can scrolling on our phones really damage your skin? And will applying creams or lotions help?
Researchers reveal CAR-enhancer therapy could help overcome cancer relapse
Pharma Times
AUGUST 2, 2024
Cancer is estimated to affect more than three million people living in the UK, according to Macmillan Cancer Support
Biotech startup Airna raises $60M for RNA editing medicines
Bio Pharma Dive
JULY 31, 2024
Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.
Takeda’s revenue climbs by 14.1% in Q1 FY2024
Pharmaceutical Technology
AUGUST 1, 2024
Takeda has reported a revenue of Y1,208bn for Q1 FY2024, a 14.1% increase from Y1,058bn in the corresponding period of FY2023.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
The Neural Signature of OCD Has Been Identified in The Human Brain
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 28, 2024
Researchers have discovered patterns in the brain that reflect the effectiveness of deep brain stimulation therapy for obsessive–compulsive disorder (OCD), potentially leading to improvements in the way that the condition is handled individually for each case.
Study reveals non-statin cholesterol drugs could reduce liver cancer risk
Pharma Times
AUGUST 2, 2024
The third leading cause of cancer mortality accounts for over 700,000 deaths every year
UniQure restructuring to claim 300 jobs
Bio Pharma Dive
AUGUST 1, 2024
The job cuts affects 65% of UniQure’s workforce and include the gene therapy developer’s recent sale of a manufacturing plant to Genezen.
Valneva and LimmaTech partner for shigellosis vaccine development
Pharmaceutical Technology
AUGUST 1, 2024
Valneva and LimmaTech have signed a deal to potentially develop the first marketed shigellosis vaccine.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Indian life sciences sector integrating technologies in R&D efforts
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 1, 2024
The Indian life sciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, big data, internet of things (IoT) and blockchain into their research and development efforts.
July 31, 2024: Gene Editing Therapies and Population Health, in This Week’s PCT Grand Rounds
Rethinking Clinical Trials
JULY 31, 2024
Dr. Adrian Hernandez In this Friday’s PCT Grand Rounds, Adrian Hernandez of Duke University will present “Precision Health to Population Health: Opportunities and Challenges for Gene Editing Therapies.” The Grand Rounds session will be held on Friday, August 2, 2024, at 1:00 pm eastern. Hernandez is a professor of medicine and vice dean in the Duke University School of Medicine and the executive director of the Duke Clinical Research Institute.
GSK cuts vaccine forecasts, while predicting faster overall growth
Bio Pharma Dive
JULY 31, 2024
Several factors are slowing U.S. sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers.
Pfizer’s Q2 2024 net income attributable to shareholders down 98%
Pharmaceutical Technology
JULY 31, 2024
Pfizer has posted a 98% decrease in net income attributable to shareholders of $41m for Q2 2024, compared to $2.3bn in Q2 2023.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
ICMR calls for proposals to commercialize CRISPR Cas-Based TB detection system
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 31, 2024
The Indian Council of Medical Research (ICMR) has announced an Expression of Interest (EoI) inviting eligible organizations, companies, and manufacturers to participate in the ‘Transfer of Technology’ for a CRISPR Cas-based TB detection system.
Study finds ovarian cancer-treated women less likely to develop breast cancer
Pharma Times
AUGUST 1, 2024
Combined, ovarian and breast cancer affect over 60,000 women in the UK every year
Ventyx’s TYK2 drug suffers second setback
Bio Pharma Dive
JULY 29, 2024
The company claimed “higher than anticipated” scores from trial volunteers on placebo led to the disappointing data, prompting it to halt internal trials.
Attralus set for amyloidosis asset’s European orphan designations
Pharmaceutical Technology
JULY 29, 2024
EMA’s COMP has adopted positive opinions for two orphan medicinal product designations for Attralus’s AT-02.
Let's personalize your content